Mind Cure Health Appoints Rob Hill To Board Of Directors

Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the firms board of directors. The appointment is said to strengthen the firms use of tech in the development of psychedelic-related treatments, given Hill’s extensive expertise in heavily regulated markets.

Hill reportedly has extensive experience in managing both private and public firms, particularly in the fields of tech, cannabis, and financial services across Canada, the US and Japan. A CPA by trade, Hill has experienced in scaling productions, operations, and restructurings. Most notably however, he reportedly has deep experience in the area of mergers and acquisitions.

This experience in M&A transactions is reportedly heavily valuable to Mind Cure, whom is focused on an aggressive growth plan which is said to include both organic and in-organic growth, such as acquisitions. His experience is also to be utilized as the company works to develop its digital therapeutics technology, with both that of iSTRYM and PsyCollage.

“We are thrilled to welcome Mr. Hill to our Board of Directors. We strongly believe in the therapeutic importance and commercial potential of technology with regards to psychedelic drugs, treatments and therapies, and continue to build a world-class technology leadership group. Mr. Hill’s track record of success in the capital markets and specific technology management expertise will add immense value to Mind Cure.”

Kelsey Ramsden, President & CEO

The appointment of Rob Hill will see Terese Gieselman step down from her role with the board. The transition is in connection with the firm refocusing its leadership to reflect its focus on key technological areas, key among which is its proprietary platforms.

Mind Cure Health last traded at $0.58 on the CSE.

FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply